Alzheimer's Disease-Related Proteins Targeted by Secondary Metabolite Compounds from Streptomyces: A Scoping Review

被引:0
|
作者
Zainuddin, Muhammad-Safuan [1 ]
Bhuvanendran, Saatheeyavaane [2 ]
Radhakrishnan, Ammu K. [2 ]
Azman, Adzzie-Shazleen [1 ]
机构
[1] Monash Univ Malaysia, Sch Sci, Bandar Sunway, Malaysia
[2] Monash Univ Malaysia, Jeffery Cheah Sch Med & Hlth Sci, Bandar Sunway, Malaysia
关键词
Alzheimer's disease; amyloid-beta; secondary metabolites; Streptomyces sp; NEUROPROTECTIVE COMPOUND; EXPRESSION; AUTOPHAGY; PATHOGENESIS; GENOTYPE; IL-10;
D O I
10.3233/ADR-230065
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: Alzheimer's disease (AD) is a neurodegenerative disease that is characterized as rapid and progressive cognitive decline affecting 26 million people worldwide. Although immunotherapies are ideal, its clinical safety and effectiveness are controversial, hence, treatments are still reliant on symptomatic medications. Concurrently, the Streptomyces genus has attracted attention given its pharmaceutically beneficial secondary metabolites to treat neurodegenerative diseases. Objective: To present secondary metabolites from Streptomyces sp. with regulatory effects on proteins and identified prospective target proteins for AD treatment. Methods: Research articles published between 2010 and 2021 were collected from five databases and 83 relevant research articles were identified. Post-screening, only 12 research articles on AD-related proteins were selected for further review. Bioinformatics analyses were performed through the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) network, PANTHER Go-Slim classification system (PANTHER17.0), and Kyoto Encyclopedia of Genes and Genomes (KEGG) Mapper. Results: A total of 20 target proteins were identified from the 12 shortlisted articles. Amyloid-beta, BACE1, Nrf-2, Beclin-1, and ATG5 were identified as the potential target proteins, given their role in initiating AD, mitigating neuroinflammation, and autophagy. Besides, 10 compounds from Streptomyces sp., including rapamycin, alborixin, enterocin, bonnevillamides D and E, caniferolide A, anhydroexfoliamycin, rhizolutin, streptocyclinone A and B, were identified to exhibit considerable regulatory effects on these target proteins. Conclusions: The review highlights several prospective target proteins that can be regulated through treatments with Streptomyces sp. compounds to prevent AD's early stages and progression. Further identification of Streptomyces sp. compounds with potential anti-AD properties is recommended.
引用
收藏
页码:1335 / 1350
页数:16
相关论文
共 50 条
  • [21] Alzheimer's Disease-related Biomarkers in Aging Adults with Down Syndrome: Systematic Review
    Bram, Jessyka Maria de Franca
    Talib, Leda Leme
    Joaquim, Helena Passarelli Giroud
    Carvalho, Claudia Lopes
    Gattaz, Wagner Farid
    Forlenza, Orestes Vicente
    CURRENT PSYCHIATRY RESEARCH AND REVIEWS, 2019, 15 (01) : 49 - 57
  • [22] Ethical issues in genomics research in persons with Alzheimer's Disease/Alzheimer's Disease-related dementia (AD/ADRD): a systematic review
    Yakubu, Aminu
    Adedeji, Isaac
    Maduka, Oluchi C.
    Jegede, Ayodele
    Adebamowo, Clement
    BMC MEDICAL ETHICS, 2024, 25 (01):
  • [23] Psychedelics for alzheimer ' s disease-related dementia: Unveiling therapeutic possibilities and pathways
    Sinha, Jitendra Kumar
    Trisal, Anchal
    Ghosh, Shampa
    Gupta, Saurabh
    Singh, Krishna Kumar
    Han, Sung Soo
    Mahapatra, Madhumita
    Abomughaid, Mosleh Mohammad
    Abomughayedh, Ali M.
    Almutary, Abdulmajeed G.
    Iqbal, Danish
    Bhaskar, Rakesh
    Mishra, Prabhu Chandra
    Jha, Saurabh Kumar
    Jha, Niraj Kumar
    Singh, Abhishek Kumar
    AGEING RESEARCH REVIEWS, 2024, 96
  • [24] Identifying Alzheimer's Disease-related miRNA Based on Semi-clustering
    Zhao, Tianyi
    Wang, Donghua
    Hu, Yang
    Zhang, Ningyi
    Zang, Tianyi
    Wang, Yadong
    CURRENT GENE THERAPY, 2019, 19 (04) : 216 - 223
  • [25] Post-translational modifications linked to preclinical Alzheimer's disease-related pathological and cognitive changes
    Abiose, Olamide
    Rutledge, Jarod
    Moran-Losada, Patricia
    Belloy, Michael E.
    Wilson, Edward N.
    He, Zihuai
    Trelle, Alexandra N.
    Channappa, Divya
    Romero, America
    Park, Jennifer
    Yutsis, Maya V.
    Sha, Sharon J.
    Andreasson, Katrin I.
    Poston, Kathleen L.
    Henderson, Victor W.
    Wagner, Anthony D.
    Wyss-Coray, Tony
    Mormino, Elizabeth C.
    ALZHEIMERS & DEMENTIA, 2024, 20 (03) : 1851 - 1867
  • [26] A multiomic approach to characterize the temporal sequence in Alzheimer's disease-related pathology
    Marttinen, Mikael
    Paananen, Jussi
    Neme, Antonio
    Mitra, Vikram
    Takalo, Mari
    Natunen, Teemu
    Paldanius, Kaisa M. A.
    Makinen, Petra
    Bremang, Michael
    Kurki, Mitja I.
    Rauramaa, Tuomas
    Leinonen, Ville
    Soininen, Hilkka
    Haapasalo, Annakaisa
    Pike, Ian
    Hiltunen, Mikko
    NEUROBIOLOGY OF DISEASE, 2019, 124 : 454 - 468
  • [27] Effects of Microglial Cytokines on Alzheimer' s Disease-Related Phenomena
    Ji, Yan
    Wang, Xiaowan
    Kalicki, Colin
    Menta, Blaise W.
    Baumgardner, Megan
    Koppel, Scott J.
    Weidling, Ian W.
    Perez-Ortiz, Judit
    Wilkins, Heather M.
    Swerdlow, Russell H.
    JOURNAL OF ALZHEIMERS DISEASE, 2019, 67 (03) : 1021 - 1034
  • [28] A scoping review of mathematical models covering Alzheimer's disease progression
    Moravveji, Seyedadel
    Doyon, Nicolas
    Mashreghi, Javad
    Duchesne, Simon
    FRONTIERS IN NEUROINFORMATICS, 2024, 18
  • [29] Suppression of Alzheimer's Disease-Related Phenotypes by Geranylgeranylacetone in Mice
    Hoshino, Tatsuya
    Suzuki, Koichiro
    Matsushima, Takahide
    Yamakawa, Naoki
    Suzuki, Toshiharu
    Mizushima, Tohru
    PLOS ONE, 2013, 8 (10):
  • [30] The immunomodulatory effects of psychedelics in Alzheimer's disease-related dementia
    Hosseini, Alireza Mohammad
    Khaleghzadeh-Ahangar, Hossein
    Rahimi, Atena
    NEUROSCIENCE, 2025, 564 : 271 - 280